

528, 453

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/029296 A2

(51) International Patent Classification⁷: C12Q 1/68

(21) International Application Number:
PCT/TR2003/000082

(22) International Filing Date:
26 September 2003 (26.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2002/02252 26 September 2002 (26.09.2002) TR

(71) Applicants and

(72) Inventors: KÖKSALAN, Orhan, Kaya [TR/TR]; Istanbul Üniversitesi Deneysel Tip Arastirma Enstisi, sü (DE-TAE) Tüberküloz Moleküler Epidemiyolojisi Birimi, Vakif Gureba Cad, Sehremini Capa 34280 (TR). KOCAGÖZ, Tanıl [TR/TR]; Acibadem Merkez Laboratuvarı, Libadiye Cad. Bogazici Sitesi Göztepe, 81190 İstanbul (TR).

(74) Agent: BULUT, Pınar; Farmapatent Danışmanlık, GMK Bulvarı N° 42/5 Leventler Apt., Maltepe 06430 (TR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/029296 A2

(54) Title: MOLECULAR SIZE MARKERS FOR SPECIES IDENTIFICATION OF MYCOBACTERIAE

(57) Abstract: This invention consists of DNA molecular size markers which are used to determine in a correct and easy way the size of DNA fragments in the evaluation step of the sizes of DNA restriction fragments separated by electrophoresis, of the hsp65 PCR-REA method used for species identification of mycobacteriae.

Molecular Size Markers for Species Identification of Mycobacteriae

5 Background of the invention:

Various mycobacterial species like *Mycobacterium tuberculosis* cause infections in humans. Antibacterial agents that are effective in the treatment of infections caused by different mycobacterial species may vary greatly. For this reason, identification of mycobacteriae 10 recovered from clinical specimens is of prime importance. As most of the mycobacteriae necessitate substantially longer times (3 to 8 weeks) to be grown in cultures, culture-based conventional identification methods like pigment formation, colony morphology and biochemical tests have the disadvantages of being slow and ambiguous. Recently, molecular identification techniques yielding unambiguous results within a few days has been 15 developed. One of these techniques, the so-called *hsp65* PRA (Polymerase chain reaction-restriction enzyme analysis) has ever gaining widespread use due to its rapidity, ease and lower cost. This method is based on the amplification of a 441bp-long fragment of the gene encoding the 65-kDA heat shock protein, digestion of the PCR products by the restriction enzymes BstEII and HaeIII, and separation of the cleaved products by agarose or better by 20 polyacrylamide gel electrophoresis. The sizes of each of the fragments are calculated by comparing them with the bands of a molecular size marker and finally comparing the resulting restriction enzyme pattern with that of known mycobacterial strains given in the algorithm.

The lack of an appropriate molecular size marker with bands exactly the same size as the 25 restriction fragments encountered in *hsp65* PCR-REA of mycobacteriae is one of the major shortcomings of this technique for, the lack of such a size marker renders visual interpretation of the restriction fragments' sizes impossible and mandates manual or software-assisted calculations. The subject of this invention is to resolve this problem by creating new molecular size markers containing fragments exactly the same size as the 30 BstEII and HaeIII digested fragments that could have been obtained in *hsp65* PCR-REA of mycobacteriae and in this way to enable the correct interpretation of the sizes of restriction

fragments separated by electrophoresis by naked eye. These products that are related to the field of molecular microbiology are not directed to diagnose a disease.

Nearly two billion people is estimated to be infected with *Mycobacterium tuberculosis* which is the most important infectious species within the *Mycobacterium* genus. Each year about 5 ten million people is contracting the disease and three million die of tuberculosis. Early detection of tuberculosis cases, their proper treatment, and breaking the transmission chain are of paramount importance for effective tuberculosis control. Proper treatment of cases can be achieved by the contribution of rapid, unambiguous identification of mycobacteriae up to species level and by determining the susceptibility patterns of the strains.

10 Despite the fact that *Mycobacterium tuberculosis* makes up the great majority of mycobacterial infections, there are several other mycobacterial species causing human infections. These bacteriae called "atypical" or "nontuberculous" mycobacteriae show great diversity in their ability to cause disease, they may be

- always pathogenic species (*Mycobacterium leprae*)
- potentially pathogenic species (*Mycobacterium avium* etc.)
- not pathogenic ones (*Mycobacterium gordonaiae* etc.)

15 Even the nonpathogenic species may be of clinical importance for, they are capable of living freely in the environment including tap water and thus may contaminate cultures which are used to diagnose the disease.

20 Identification of mycobacteriae to the species level is important for patient management, as the results obtained influence the decision to treat or not to treat the patient, the choice of proper treatment and the eventual need for patient isolation.

25 Classical identification methods based on culture and biochemical tests may take weeks to months after reception of specimens and the tests sometimes fail to produce a precise identification. Genotypic methods for the identification of mycobacteriae has been developed in recent years. These molecular methods are of increasing importance because they yield rapid and, mostly, unequivocal results.

30 Molecular techniques based on probe hybridization or on amplification of specific genomic region provide results limited to a single species per experiment. Limited number of commercially available probes that are used in probe hybridization technique restricts the differentiating power of this technique with only a few species, the remaining -approx. 90-

mycobacterial species cannot be identified and additionally, each extra probe used to identify the isolate adds an extra cost.

In contrast to the above-mentioned techniques needing specialized equipment, PCR-restriction fragment length polymorphism analysis (PRA) of the *hsp65* gene present in all

5 mycobacteriae offers an easy, rapid and inexpensive procedure to identify most of the mycobacterial species in a single experiment. Although *hsp65* gene is present in all mycobacteriae, the nucleic acid sequence of *hsp65* in each species varies from the others. These variances are made discernible by restriction enzymes that recognize specific DNA sequences and cut the DNA at these sites.

10 In PRA, a 441base pair (bp) portion "*Telenti fragment*" of *hsp65* gene is amplified, the amplified products will then be separated into two microcentrifuge tubes and digested by the restriction enzymes *BstEII* and *HaeIII*. The digested DNA fragments and a molecular size marker are loaded onto a gel, run in electrophoresis buffer and thus are separated from each other.

15 The sizes of each of the digested fragments are determined by comparing them with the bands of the molecular size marker whose band sizes are known. In order to achieve more accurate size calculations, this comparison are carried out by using sophisticated computer programs.

20 The molecular size markers which are the subject of this invention contain fragments exactly the same size as the restriction fragments of mycobacteriae. These molecular size markers specific to PRA of mycobacteriae alleviates the accurate size determination of tested mycobacterial strains' restriction fragments without the need for sophisticated computer programs.

25 **Previously available products (molecular size markers)**

Electrophoresis is a molecular biological technique that is widely used in determining the sizes of macromolecules. In this technique, electrically charged molecules are run within a cell-forming gel by the application of electrical voltage. During their run through the pores 30 of the gel, molecules are propelling with different velocities depending to the resistance they are facing. For DNA molecules, this velocity is inversely proportional to the logarithm of their sizes. The determination of DNA fragments' sizes separated by electrophoresis is achieved by using molecular size markers that are run in adjacent lanes of the same gel as

the DNA fragments of concern and whose fragment sizes are known. For the precise determination of DNA fragments in question, molecular size markers should ideally contain fragments exactly the same size as the tested DNA fragments or at least fragments similar to the sizes of the DNA in concern. This is the reason why commercially available molecular 5 size markers are far from being useful; they do not contain fragments exactly the same size as the tested DNA fragments which renders impossible the easy visual interpretation of digested mycobacterial DNA fragments and separated by electrophoresis; sophisticated software packages are needed to obtain "nearly correct" fragment sizes.

It is common practice to obtain molecular size markers by digestion of bacteriophages 10 having short DNA sequences with restriction enzymes. The most frequently used molecular size marker in published *hsp65* PRA studies, is HaeIII-digested Φ X174 bacteriophage DNA which is easily reproducible in *E.coli*. This marker contains eleven fragments which are 1352, 1078, 872, 603, 310, 281, 271, 234, 194, 118, 72 base pairs long. Digesting the 441bp long fragment of the *hsp65* gene either by BstEII or HaeIII results in several shorter 15 fragments which mostly range between 50-200 base pairs and are close to each other in size. The size marker Φ X174/HaeIII has only three bands within this range (194, 118 and 72 bp). Additionally these three bands are not identical to mycobacterial fragments in size. In brief, the presence of a few non-identical fragments renders Φ X174/HaeIII marker unsuitable for PRA.

20 In comparison, another molecular size marker, Φ X174/HinfI, seems to be more appropriate for PRA; it has relatively more bands within the size range of 50-200bp. However, none of the bands of this marker (726, 713, 553, 500, 427, 417, 413, 311, 249, 200, 151, 140, 118, 100, 82, 66, 48, 42, 40 ve 24 bp) is identical to mycobacterial restriction fragments.

25 Although the main determinant of the electrophoretic ability of a fragment is its size, the composition of the DNA (GC/AT content) also plays some role. GC/AT content of mycobacteriae is very different from the GC/AT content of bacteriophages This leads to another erratic calculation of the fragment sizes.

The purpose of the invention:

30 The purpose of this invention is to obtain DNA molecular size markers that will be used in the correct and easy interpretation of the sizes of restriction fragments of 441bp region of *hsp65* gene amplified by PCR and digested by BstEII and HaeIII enzymes, by

electrophoretic analysis. For convenience the two molecular size marker are called Marker-B and Marker-H. Marker B contains 8 different size fragments of 441, 325, 231, 210, 131, 116, 94 and 79 bp (Figure 1). Marker-H contains 14 different size fragments of 185, 161, 152, 139, 127, 103, 87, 69, 59, 58, 42, 40, 36 and 34bp (Figure 2).

5 In figure 1 Marker B is shown together by restriction fragments obtained by PCR amplification of hsp65 gene of several species of mycobacteriae and digestion by BstEII enzyme and separated by electrophoresis using 6% polyacrilamide gel.

In figure 2 Marker H is shown together by restriction fragments obtained by PCR amplification of hsp65 gene of several species of mycobacteriae and digestion by HaeIII enzyme and separated by electrophoresis using 8% polyacrilamide gel.

10

Detailed Description of the Invention

15 For obtaining two molecular size markers standards *M. simiae*, *M. smegmatis*, *M. gallinarum*, *M. intracellulare*, *M. terrae* are used to prepare Marker B and *M. simiae*, *M. gallinarum*, *M. chitae*, *M. xenopi* are used to prepare Marker-H.

Isolation of DNA from mycobacteriae:

20 A few mycobacterial colonies from freshly grown cultures are suspended in TE buffer (10mM Tris pH 8.0, 1mM EDTA) in plastic microcentrifuge tubes. The suspension is centrifuged at 12000g for 1 minute to sediment the bacteria and the supernatant is discarded. The bacteria are washed twice by repeating the same process. The final bacterial sediment is suspended in 250 μ l TE buffer. The tubes are incubated in a boiling water bath for 20 minutes to lyse the bacteria and release DNA. Cell debris are sedimented by centrifugation and the 25 supernatant which contains mycobacterial DNA is transferred to a clean tube. This DNA is used as template for amplification of hsp65 gene by PCR.

PCR amplification of hsp65 gene:

30 The template DNA obtained from mycobacteriae is mixed in appropriate concentrations of Taq polymerase enzyme, deoxynucleotide triphosphates, enzyme reaction buffer and the primers TB11 (5' ACC AAC GAT GGT GTG TCC AT 3') and TB12 (5' CTT GTC GAA CCG CAT ACC CT 3'). Reaction tubes are placed in a thermal cycler. After denaturation for 5 minutes at 95°C, 40 cycles consisting of 30 seconds at 94°C, for denaturation, 45 seconds

at 54°C for primer annealing and 90 seconds at 72°C for polymerization is done. Ten minutes at 72°C is added to the end, to complete possible incomplete strands.

Purification of DNA amplification products:

5 The 441 base pairs (bp) amplified region of mycobacterial hsp65 gene regions are separated in 1% agarose gel by electrophoresis, stained by ethidium bromide and visualized by ultraviolet light. The bands containing these DNA fragments are cut and agarose is solubilized in sodium iodide solution by heating. The released DNA are sedimented by binding to glass milk. After several wash steps DNA is solubilized in sterile deionized water.

10

Molecular Cloning:

PCR products are cloned into PCR products cloning plasmid vector. For this purpose purified hsp65 gene region are mixed with the plasmid vector and ligated to each other by adding ligase enzyme, enzyme buffer and ATP. The cloned plasmids are introduced into 15 competent E. coli cells. Transformed bacteria are multiplied by culturing and stocks are stored at -85°C.

Plasmid Isolation:

Fresh cultures are prepared from bacterial stocks. Overnight cultures are used for plasmid 20 isolation. Plasmids are purified by alkaline lysis method. For this purpose, bacteria are suspended in glucose-tris-EDTA buffer and lysed by NaOH-SDS solution. Cell walls, proteins and chromosomal DNA are sedimented by potassium acetate. Supernatant that contains plasmid DNA and RNAs is transferred into a clean tube. RNA is eliminated by the addition of RNase.

25

Preparation of Molecular Size markers:

The 441bp gene region is amplified by PCR, as described above, using hsp65 gene cloned 30 plasmids as template. To prepare Marker-B PCR products obtained from plasmids containing hsp65 gene from M. simiae, M. smegmatis, M. gallinarum, M. intracellulare, M. terrae are mixed with restriction enzyme BstEII, enzyme buffer and incubated 24 hours at 60°C. To prepare Marker-H PCR products obtained from plasmids containing hsp65 gene from M. tuberculosis, M. simiae, M. gallinarum, M. chitae, M. xenopi are mixed with restriction enzyme HaeIII, enzyme buffer and incubated 24 hours at 37°C. The products

obtained are mixed with gel loading buffer to make them ready to use in electrophoresis. Marker-B obtained this way contains 8 DNA fragments of sizes 441, 325, 231, 210, 131, 116, 94 ve 79 bp (Figure 1) and Marker-H contains 14 DNA fragments of sizes 185, 161, 152, 139, 127, 103, 87, 69, 59, 58, 42, 40, 36, 34 bp.

CLAIMS

- 1- A DNA molecular size marker that contains DNA fragments which are 441, 325, 231, 210, 131, 116, 94 and 79 base pairs long (Figure 1-Marker B).
- 2- The production of molecular size marker in claim 1 is done by isolation of DNA from mycobacteriae, amplification of hsp65 gene by PCR, purification of DNA amplification products, molecular cloning, plasmid isolation and restriction enzyme digestion.
- 5 3- The species of mycobacteriae used for DNA isolation referred in claim 2 for production of the molecular size marker in claim 1, are the ones which produce the required size fragments indicated in claim 1.
- 10 4- The species of mycobacteriae referred in claim 3 which are used for production of molecular weight marker referred in claim 1 are *M. simiae*, *M. smegmatis*, *M. gallinarum*, *M. intracellulare*, *M. terrae*.
- 5- The primers used in amplification of hsp65 gene referred in claim 2 are TB11 (5' ACC AAC GAT GGT GTG TCC AT 3'), and TB12 (5' CTT GTC GAA CCG CAT ACC CT 3').
- 15 6- The restriction enzyme indicated in claim 2 is BstEII.
- 7- Molecular size marker indicated in claim 1 is used in determining the size of restriction fragments obtained by BstEII digestion, in the step of electrophoretic analysis of hsp65 PCR-REA (Polymerase Chain Reaction – Restriction Enzyme Analysis) method.
- 8- A DNA molecular size marker that contains DNA fragments which are 185, 161, 152,
- 20 139, 127, 103, 87, 69, 59, 58, 42, 40, 36 and 34 base pairs long (Figure 2- Marker H).
- 9- The production of molecular size marker in claim 8 is done by isolation of DNA from mycobacteriae, amplification of hsp65 gene by PCR, purification of DNA amplification products, molecular cloning, plasmid isolation and restriction enzyme digestion.
- 10- The species of mycobacteriae used for DNA isolation referred in claim 9 for production
- 25 of the molecular size marker in claim 8, are the ones which produce the required size fragments indicated in claim 8.
- 11- The species of mycobacteriae referred in claim 10 which are used for production of molecular weight marker referred in claim 8 are *M. tuberculosis*, *M. simiae*, *M. gallinarum*, *M. chitae*, *M. xenopi*.
- 30 12- The primers used in amplification of hsp65 gene referred in claim 9 are TB11 (5' ACC AAC GAT GGT GTG TCC AT 3'), and TB12 (5' CTT GTC GAA CCG CAT ACC CT 3').
- 13- The restriction enzyme indicated in claim 9 is HaeIII.

14- Molecular size marker indicated in claim 8 is used in determining the size of restriction fragments obtained by HaeIII digestion, in the step of electrophoretic analysis of hsp65 PCR-REA (Polymerase Chain Reaction – Restriction Enzyme Analysis) method.

1/2




Figure 1. Marker B together with DNA restriction fragments obtained BstEII digestion of 441bp region of hsp65 gene amplified by PCR from several species of mycobacteria.

2/2




Figure 2. Marker H together with DNA restriction fragments obtained HaeIII digestion of 441bp region of hsp65 gene amplified by PCR from several species of mycobacteria.